BGI Genomics disclosed its third quarter report on the evening of October 25th, 2024. The company achieved revenue of 2.826 billion yuan in the first three quarters of 2024, a year-on-year decrease of 10.1%. The net income attributable to the parent company was a loss of 0.124 billion yuan, compared to 70.3525 million yuan in the same period last year. The net income attributable to the parent company in the third quarter was a loss of 0.142 billion yuan. The main reasons for the performance decline include: (1) The company's low-price benevolence policy for livelihood projects and adjustments in product structure led to a 3.07% decrease in gross margin compared to the same period last year. (2) In the first three quarters of 2024, influenced by the overall economic environment, the company's accounts receivable collection progress fell short of expectations, leading to an increase of 89.69 million yuan in credit impairment losses compared to the same period last year. (3) The company recognized an investment loss of approximately 44.1 million yuan in equity-accounted investees, compared to a 4.59 million yuan investment loss in the same period last year, representing a year-on-year increase in investment losses of 39.51 million yuan.